Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion.
-
Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...
-
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below...
-
Our findings demonstrate that PRP exerts multifaceted effects specifically over the cancer associated fibroblasts (CAFs) population and tumor cells.
-
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711
-
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine...
-
Annovis will begin Open-Label Extension study in Parkinson's disease patients
-
SYDNEY, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that due to the recent accelerated screening and enrolment in the XanaMIA phase 2b/3 Alzheimer’s disease (AD)...
-
OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no...
-